Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Megan Greally"'
Autor:
Lynda M. McSorley, Mehala Tharmabala, Fathiya Al Rahbi, Fergus Keane, Denis Evoy, James G. Geraghty, Jane Rothwell, Damian P. McCartan, Megan Greally, Miriam O’Connor, Deirdre O’Mahony, Maccon Keane, Michael John Kennedy, Seamus O’Reilly, Steve J. Millen, John P. Crown, Catherine M. Kelly, Ruth S. Prichard, Cecily M. Quinn, Janice M. Walshe
Publikováno v:
Current Oncology, Vol 31, Iss 3, Pp 1302-1310 (2024)
Background: This study, using real-world data, assesses the impact of RS testing on treatment pathways and the associated economic consequences of such testing. This paper pertains to lobular breast cancer. Methods: A retrospective, observational stu
Externí odkaz:
https://doaj.org/article/c7e991104cdb4851bf2dfdfc09b20e5d
Autor:
Gavin P. Dowling, Sinead Toomey, Philip Bredin, Imelda Parker, Eibhlin Mulroe, Jacinta Marron, Olivia McLoughlin, Ausra Teiserskiene, Colm Power, Anne Marie O’Shea, Megan Greally, Patrick G. Morris, Deirdre Duke, Arnold D. K. Hill, Bryan T. Hennessy
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background The current standard of care in the neoadjuvant setting for high-risk HER2-positive (HER2 +) breast cancer is to combine systemic chemotherapy with dual HER2 blockade, trastuzumab and pertuzumab. Targeted therapies have significan
Externí odkaz:
https://doaj.org/article/525da2fab1674ea289c10763a6526868
Autor:
Hannah E Forde, Niamh Mehigan-Farrelly, Katie Ryan, Tom Moran, Megan Greally, Austin G Duffy, Maria M Byrne
Publikováno v:
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-5 (2021)
A 41-year-old male presented to the Emergency Department with a 6-month history of back and hip pain. Skeletal survey revealed bilateral pubic rami fractures and MRI of the spine demonstrated multiple thoracic and lumbar fractures. Secondary work up
Externí odkaz:
https://doaj.org/article/69ac8d7ae89341e8a736017a4b643018
Autor:
Vetri Sudar Jayaprakasam, Peter Gibbs, Natalie Gangai, Raazi Bajwa, Ramon E. Sosa, Randy Yeh, Megan Greally, Geoffrey Y. Ku, Marc J. Gollub, Viktoriya Paroder
Publikováno v:
Cancers, Vol 14, Iss 12, p 3035 (2022)
This study aimed to assess the usefulness of radiomics features of 18F-FDG PET/CT in patients with locally advanced esophageal cancers (ESCC) in predicting outcomes such as clinical tumor (cT) and nodal (cN) categories, PET response to induction chem
Externí odkaz:
https://doaj.org/article/626d29562d7045738c4d4afdbe09b949
Autor:
Fergus Keane, Megan Greally, Anne Horgan, Karen Duffy, Maeve Lowery, Petra Martin, Liam Grogan, Nemer Osman, Derek G. Power, Saira Nasim, Eileen M. O’Reilly, Gregory Leonard
Publikováno v:
Irish Journal of Medical Science (1971 -). 192:575-589
Improvements in early detection, screening and treatment of cancer have resulted in a significant improvement in cancer mortality and an increase in the number of cancer survivors globally. Accordingly, a significant rise in the number of cancer surv
Autor:
Geoffrey Y. Ku, Yelena Y. Janjigian, Nikolaus Schultz, Luis A. Diaz, David B. Solit, Laura H. Tang, Michael F. Berger, David H. Ilson, David P. Kelsen, Marc Ladanyi, Foysal Daian, Ritika Kundra, Yaelle Tuvy, Jaclyn F. Hechtman, Marinela Capanu, Matthew Margolis, Walid K. Chatila, Joanne F. Chou, Megan Greally
Purpose:Immune checkpoint inhibitors (ICI) are effective in only a minority of patients with esophagogastric cancer (EGC). Here, we aimed to identify predictors of durable clinical benefit to ICI in EGC.Experimental Design:Patients with advanced EGC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b68fddf69e422bf0d0412fd1887fa03
https://doi.org/10.1158/1078-0432.c.6527844.v1
https://doi.org/10.1158/1078-0432.c.6527844.v1
Autor:
Geoffrey Y. Ku, Yelena Y. Janjigian, Nikolaus Schultz, Luis A. Diaz, David B. Solit, Laura H. Tang, Michael F. Berger, David H. Ilson, David P. Kelsen, Marc Ladanyi, Foysal Daian, Ritika Kundra, Yaelle Tuvy, Jaclyn F. Hechtman, Marinela Capanu, Matthew Margolis, Walid K. Chatila, Joanne F. Chou, Megan Greally
PFS analysis by gene alteration occurring in 10% or more of MSS patients who received combination therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04d1c7069b1c947a9a1bb198059dd8c6
https://doi.org/10.1158/1078-0432.22471302
https://doi.org/10.1158/1078-0432.22471302
Autor:
Ryan H. Moy, Megan Greally, Joanne F. Chou, Jia Li, Avni M. Desai, Sree B. Chalasani, Elizabeth Won, David P. Kelsen, David H. Ilson, Yelena Y. Janjigian, Marinela Capanu, Geoffrey Y. Ku
Publikováno v:
Cancer Chemotherapy and Pharmacology. 89:255-265
Autor:
Megan Greally, Luis A. Diaz, David B. Solit, Yaelle Tuvy, Laura H. Tang, David P. Kelsen, David H. Ilson, Geoffrey Y. Ku, Michael F. Berger, Jaclyn F. Hechtman, Marinela Capanu, Foysal Daian, Ritika Kundra, Nikolaus Schultz, Joanne F. Chou, Walid K. Chatila, Yelena Y. Janjigian, Marc Ladanyi, Matthew Margolis
Publikováno v:
Clinical Cancer Research. 25:6160-6169
Purpose: Immune checkpoint inhibitors (ICI) are effective in only a minority of patients with esophagogastric cancer (EGC). Here, we aimed to identify predictors of durable clinical benefit to ICI in EGC. Experimental Design: Patients with advanced E
Autor:
Ryan H, Moy, Megan, Greally, Joanne F, Chou, Jia, Li, Avni M, Desai, Sree B, Chalasani, Elizabeth, Won, David P, Kelsen, David H, Ilson, Yelena Y, Janjigian, Marinela, Capanu, Geoffrey Y, Ku
Publikováno v:
Cancer chemotherapy and pharmacology. 89(2)
Paclitaxel plus ramucirumab is a standard second-line regimen for patients with advanced gastric adenocarcinoma, but clinical benefit remains modest. One potential resistance mechanism to VEGFR2 inhibition is activation of the PDGF/PDGFR pathway, whi